Immunolocalisation of Cripto and Amphiregulin in Rectal Cancer: correlation with Prognosis
Pathology and Microbiology
We have examined the expression of two newly identified members of the EGF family, cripto and amphiregulin (AR), in a series of 58 primary rectal carcinomas and adjacent non-involved mucosa by immunohistochemical staining using rabbit polyclonal antibodies. More than 90% (53/58) of rectal carcinomas showed AR immunoreactivity whereas cripto was found in 41 out of 58 (71%) tumours. Cripto immunoreactivity was most frequently seen in tumours arising in the lower third of the rectum (p<0.01) and in flat and excavated lesions (p<0.05). Out of 54 normal rectal mucosae adjacent to carcinoma 20 (37%) showed cripto immunoreactivity and all showed a trend towards a higher recurrence rate. Ten of these 20 (50%) rectal tumours showed less cripto immuno-reactivity than the adjacent normal mucosa and were penetrating through the bowel wall and recurred within 5 years. There was a correlation between increased cripto immunoreactivity in the normal mucosa and lymph node involvement (p=0.01). AR immunoreactivity was present in the majority (52/58, 94%) of the normal mucosae adjacent to tumours. No correlation was found between AR immunostaining, histology and prognosis.
International Journal of Oncology
Talbot, I. C.,
Northover, J. M.,
Stamp, G. W.,
Gullick, W. J.,
(1994). Immunolocalisation of Cripto and Amphiregulin in Rectal Cancer: correlation with Prognosis. International Journal of Oncology, 4(4), 865-871.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/400